Combined Psoriasis Therapy Could Improve Metabolic Health
Adults with psoriasis may see blood pressure benefits by pairing biologics with GLP-1 agonists for treatment.
Updated on Oct. 16, 2026 in Weight Loss
Live Poll
Should doctors prioritize weight management alongside skin treatment when caring for patients with chronic psoriasis?
New research suggests that integrating GLP-1 agonists with biologic therapies may help manage metabolic health in patients with psoriasis. This combined approach aims to address systemic inflammation and obesity-related risks in those living with the skin condition.
Why it matters
Psoriasis patients often face higher risks of stroke and coronary disease due to untreated metabolic issues, which can also contribute to biologic treatment failure. Addressing these weight-related comorbidities is crucial, as systemic inflammation frequently persists even after skin clearance.
Data from the TOGETHER-PsO trial showed that patients receiving the combination of ixekizumab and tirzepatide experienced a blood pressure reduction of 8 to 10 mm Hg. The findings were presented at the Fall Clinical 2026 conference.
The players
Joel Gelfand
A researcher who presented data on managing metabolic comorbidities in psoriatic disease.
The details
The treatment protocol involves combining ixekizumab, a biologic for psoriasis, with tirzepatide, a GLP-1 agonist. By using these therapies together, clinicians aim to reduce excess weight and systemic inflammation. This is particularly important because obesity is strongly linked to both the development of psoriatic arthritis and the failure of conventional biologic treatments for skin clearance.
Timeline
October 2026: The Fall Clinical 2026 conference was held.
Health Landscape
This research aligns with the TOGETHER-PsO trial to improve outcomes for patients with inflammatory diseases. It marks a shift toward addressing metabolic health as a standard component of managing long-term psoriatic disease.
If you are currently on a biologic for psoriasis and struggle with metabolic issues, it is worth discussing the potential risks and benefits of combined therapies with your dermatologist or rheumatologist. Patients should continue to track blood pressure and weight markers alongside their skin health.
The takeaway
Addressing metabolic health is a vital step in managing the systemic nature of psoriatic disease. Patients should prioritize keeping an open dialogue with their care team about whether their treatment plan accounts for potential cardiovascular and weight-related risks.
Further reading
For more information on managing metabolic health, visit our Weight Loss section.
Source note: This article includes information reported by Dermatologytimes.
Live Poll
Should doctors prioritize weight management alongside skin treatment when caring for patients with chronic psoriasis?
